Andy Chen

Q: What is Andy Chen's success rate?

Andy Chen currently has a success rate of 80.23332945424367.

Q: What is the average return of Andy Chen's calls?

Their stock ratings have generated an average return of 55.94009509893438.

Wolfe Research | Healthcare

Andy Chen is an analyst from Wolfe Research specializing in the Healthcare sector. Ranked #352 out of 4571 analysts, they have issued 16 stock ratings with a success rate of 80.23% and an average return of 55.94%.

With 16 ratings to date, Andy Chen is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 80.23% and an average return of 55.94%, highlighting promising potential as their track record develops further.

#352

Out of 4571

Total Ratings

+80.23%

Success Rate

+55.94%

Average Return

Recent Ratings Analysis

VERA

Buy

Mar 11, 2026

Target

$88.00

Current

$42.04

Performance

0.00%

Andy Chen rated VERA as Outperform on Mar 11, 2026, setting a price target of 88. Shares have remained stable near 42.04, leaving the 88 target still in play.

APGE

Hold

Jan 07, 2026

Target

$0.00

Current

$74.68

Performance

-5.41%

On Jan 07, 2026, APGE was given a Peer Perform rating by Andy Chen, with a target price of null. The rating provided protection from downside risk as the stock fell to 74.68.

VRTX

Buy

Jan 06, 2026

Target

$548.00

Current

$492.38

Performance

5.12%

VRTX received a Outperform rating from Andy Chen on Jan 06, 2026, aiming for 548. Momentum has favored the Buy call, with shares climbing from 492.38 to 492.38, rewarding those who trusted the recommendation.

IMVT

Buy

Jan 06, 2026

Target

$50.00

Current

$25.56

Performance

-1.31%

On Jan 06, 2026, Andy Chen published a Outperform outlook on IMVT, with a target of 50. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 25.56.

KYMR

Hold

Jan 06, 2026

Target

$0.00

Current

$81.52

Performance

10.97%

Andy Chen on Jan 06, 2026 assigned KYMR a Peer Perform rating, with a price target of null. Shares outperformed expectations, climbing 10.97% despite the neutral view.

ARGX

Hold

Nov 24, 2025

Target

$0.00

Current

$728.09

Performance

-19.70%

On Nov 24, 2025, Andy Chen reaffirmed ARGX with a Peer Perform rating, targeting null. The Hold stance reflected market caution that was later justified.

NTLA

Hold

Nov 12, 2025

Target

$0.00

Current

$13.01

Performance

37.09%

NTLA was rated Peer Perform by Andy Chen on Nov 12, 2025, with a price objective of null. Despite caution, upside momentum rewarded risk-takers with gains to 13.01.

APLS

Hold

Nov 06, 2025

Target

$0.00

Current

$19.38

Performance

-1.67%

On Nov 06, 2025, Andy Chen initiated coverage on APLS with a Peer Perform rating and target of null. The stock’s lack of movement around 19.38 aligned with a cautious approach.

AKRO

Hold

Oct 10, 2025

Target

$0.00

Current

$54.65

Performance

1.43%

Andy Chen issued a Peer Perform recommendation for AKRO on Oct 10, 2025, price target set at null. The rating was appropriate for a consolidating market trading near 54.65.

ETNB

Hold

Sep 19, 2025

Target

$0.00

Current

$14.84

Performance

-0.20%

On Sep 19, 2025, ETNB was evaluated by Andy Chen, who gave a Peer Perform rating and target of null. Hold sentiment was validated by subdued trading with no breakout beyond 14.84.

ALNY

Hold

Aug 04, 2025

Target

$0.00

Current

$320.43

Performance

-23.63%

Andy Chen rated ALNY as Peer Perform on Aug 04, 2025, setting a price target of null. The cautious Hold call aligned with subsequent weakness, as shares slipped 23.63%.

VRNA

Buy

Jul 01, 2025

Target

$170.00

Current

$106.91

Performance

18.16%

On Jul 01, 2025, VRNA was given a Outperform rating by Andy Chen, with a target price of 170. The stock rallied 18.16% after the rating, narrowing the gap to the target of 170 and validating the bullish stance.

BBIO

Buy

Jun 17, 2025

Target

$49.00

Current

$71.39

Performance

78.16%

BBIO received a Outperform rating from Andy Chen on Jun 17, 2025, aiming for 49. Momentum has favored the Buy call, with shares climbing from 71.39 to 71.39, rewarding those who trusted the recommendation.

SRPT

Hold

Jun 17, 2025

Target

$0.00

Current

$17.57

Performance

-18.48%

On Jun 17, 2025, Andy Chen published a Peer Perform outlook on SRPT, with a target of null. Weakness in the stock, now at 17.575, supported the conservative rating.

RNA

Buy

Jun 17, 2025

Target

$55.00

Current

$14.80

Performance

-49.59%

Andy Chen on Jun 17, 2025 assigned RNA a Outperform rating, with a price target of 55. The call has struggled to gain traction, with shares losing 49.59%.

ANAB

Buy

Feb 04, 2025

Target

$0.00

Current

$64.67

Performance

291.70%

On Feb 04, 2025, Andy Chen reaffirmed ANAB with a Outperform rating, targeting null. The recommendation was supported by strong follow-through as the stock rose from 64.67 to 64.67.

ZBIO

Buy

Feb 04, 2025

Target

$19.00

Current

$25.34

Performance

230.81%

ZBIO was rated Outperform by Andy Chen on Feb 04, 2025, with a price objective of 19. A bullish response from the market helped close the gap of -6.34 to the target.

ORKA

Buy

Feb 04, 2025

Target

$20.00

Current

$34.41

Performance

142.15%

On Feb 04, 2025, Andy Chen initiated coverage on ORKA with a Outperform rating and target of 20. The stock’s climb of 142.15% since the call highlights the foresight in the rating.

CRNX

Hold

Feb 04, 2025

Target

$0.00

Current

$36.98

Performance

-8.47%

Andy Chen issued a Peer Perform recommendation for CRNX on Feb 04, 2025, price target set at null. Market action validated the conservative Hold outlook with shares at 36.98.

INCY

Buy

Oct 01, 2024

Target

$0.00

Current

$94.66

Performance

39.08%

On Oct 01, 2024, INCY was evaluated by Andy Chen, who gave a Outperform rating and target of null. This case illustrates how a timely bullish rating can translate into tangible gains of 39.08%.

CLDX

Hold

Sep 27, 2024

Target

$0.00

Current

$31.23

Performance

-5.93%

Andy Chen rated CLDX as Peer Perform on Sep 27, 2024, setting a price target of null. The cautious Hold call aligned with subsequent weakness, as shares slipped 5.93%.

MLTX

Hold

Aug 26, 2024

Target

$0.00

Current

$17.84

Performance

-62.96%

On Aug 26, 2024, MLTX was given a Peer Perform rating by Andy Chen, with a target price of null. The rating provided protection from downside risk as the stock fell to 17.84.

MDGL

Buy

Jun 11, 2024

Target

$0.00

Current

$431.53

Performance

47.79%

MDGL received a Outperform rating from Andy Chen on Jun 11, 2024, aiming for null. Momentum has favored the Buy call, with shares climbing from 431.53 to 431.53, rewarding those who trusted the recommendation.

VRDN

Buy

Jun 11, 2024

Target

$0.00

Current

$28.62

Performance

112.63%

On Jun 11, 2024, Andy Chen published a Outperform outlook on VRDN, with a target of null. Shares gained 112.63%, underscoring the accuracy of the bullish outlook toward null.

RAPT

Hold

May 14, 2024

Target

$0.00

Current

$58.01

Performance

81.27%

Andy Chen on May 14, 2024 assigned RAPT a Peer Perform rating, with a price target of null. Shares outperformed expectations, climbing 81.27% despite the neutral view.

Frequency Asked Questions

Who is Andy Chen?

Andy Chen is an analyst from Wolfe Research specializing in the Healthcare sector.

What is Andy Chen's success rate?

Andy Chen currently has a success rate of +80.23%.

How many ratings has Andy Chen issued?

Andy Chen has issued 16 stock ratings so far.

What is the average return of Andy Chen's calls?

Their stock ratings have generated an average return of +55.94%.

What is Andy Chen's ranking?

Andy Chen is ranked #352 out of 4571 analysts.

What types of ratings does Andy Chen give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Andy Chen?

You can follow Andy Chen by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Andy Chen?

Their latest rating was a Buy on VERA issued on 2026-03-11.